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Editorial on the Research Topic
Autism SpectrumDisorders (ASD)-Searching for the Biological Basis for Behavioral Symptoms
and New Therapeutic Targets
The frequency of Autism Spectrum Disorders (ASDs) is increasing with a 30% reported increase
in pediatric prevalence from 2012 to 2014 in the U.S. until present rates of about 1 in 68 children
or 1.5% of children in the U.S. (Corcoran et al., 2015). Yet, little is known about the etiology of
this spectrum. As of now, ASD is diagnosed based on a series of behavioral tests. The challenge
for researchers is to try to uncover the biological basis for these typical behaviors in order to
improve diagnosis and identify potential targets for treatment. A multidisciplinary approach to
understanding the biological basis for the behavioral symptoms is necessary in order to move
forward. This includes analysis of the current animal models for ASD and their suitability,
reviewing behavioral, immunological, immunogenetic, and epigenetic research, reassessing clinical
diagnostic tools, and surveying radiological, pathological, and serological records for clues.
With over 500 animal models available with varying construct validity and face validity, and
a variety of behavioral tests for animals (Kazdoba et al., 2016; three chamber, T maze, elevated
plus maze) and for humans (ADOS, ADIR, CARS, ABC) and still no FDA approved effective
treatments for the core symptoms of autism, much more needs to be done to understand the
behavioral features of autism and their underlying etiology. Thillay et al. used EEG to record
12 adults diagnosed with ASD and age matched controls performing a visual target detection
task. Their data suggests that patients diagnosed with autism overreact to stimuli coming from
an unclear context, which matches their sense of being overwhelmed by incoming data, and that
they are unable to control cortical activity according to varying levels of uncertainty. Parallel to
the response to an uncertain context, Corbett et al. investigated the difference in stress response
to interaction with peers as well as the role of sensory sensitivity. They found that children with
ASD showed significantly higher cortisol levels than their typically developing control group.
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These results indicated that increased cortisol was associated
with increased sensory sensitivity and enhanced stress.
Schauder and Bennetto integrated the empirical literature
on sensory processing in ASD with those papers that investigate
neural response to sensory stimuli. Sensory symptoms start
demonstrating relationships with adaptive functioning and
language proficiency in the early years. Therefore, in order to
generate a multidisciplinary approach to sensory processing
in ASD, it is critical to integrate the sensory symptoms and
neuroscience perspectives. Internal and external stimuli can
elicit two different categories of responses, an excitatory
response, and an inhibitory response. Frye et al. reviewed
biological abnormalities shared by ASD and epilepsy and
found that autism and epilepsy are associated with comparable
aberrations that may alter the excitatory to inhibitory balance of
the cortex. They suggested that these parallels may explain the
high prevalence of epilepsy in ASD and the elevated prevalence
of ASD features in individuals with epilepsy. Instead of looking
at other disorders that are similar to autism such as epilepsy,
Zachor and Ben-Itzchak set out to investigate whether specific
medical conditions in ASD are associated with unique behavior
profiles. They found two unique medical behavioral subtypes
in ASD that affect inherited traits of cognition and/or autism
severity. Crespi analyzed the innovative hypothesis that autism
is actually a disorder of high intelligence. They propose that
looking at both intelligence and autism studies together could
provide unique insights into the neurological and genetic causes
of high mental abilities.
Efforts at twin studies, identifying HLA associations, specific
genes, single nucleotide variants (SNVs) or single nucleotide
polymorphisms (SNPs), and hotspots for copy number variations
(CNVs) in autism have yielded limited but promising results
so far. In light of the fact that Rett Syndrome, Fragile
X, and other genetic syndromes comorbid with ASD have
been shown to be associated with epigenetic modifications
the theory that epigenetic mechanisms might potentially be
associated with the etiology of ASD deserves more attention.
Due to mounting evidence indicating immune involvement
in the etiology of autism, Torres et al. looked at common
genetic variants found in HLA and KIR immune genes,
particularly HLA genes on chromosome 6 and KIR genes
on chromosome 9. They show that for HLA class I alleles,
frequencies are significantly increased by more than 5% over
control populations. They also found that three activating KIR
genes have increased frequencies of 15, 22, and 14% in the
autism populations, and that there is a 6% increase in total
activating KIR genes in autism when compared to controls.
Similarly, Gamliel et al. performed a study comparing the
KIR:HLA frequencies in ASD children with those of their
healthy parents. They found a higher frequency of HLA-C2
allotypes among the fathers, while its corresponding ligand
2DS1, was higher in the maternal group. Francis et al. also
looked at genetic variants, yet they focused on the receptor
genes of oxytocin and vasopressin, since studies have reported
significant associations between these genes and ASD diagnosis
and ASD-related phenotypes. They found associations between
vasopressin receptor single nucleotide polymorphisms (SNPs)
and specific oxytocin receptor SNPs and diagnosis and behavioral
profile. Instead of looking at specific genetic variants, Ansel
et al.) analyzed gene expression studies from the past decade
and came up with a comprehensive list of genes that were found
to be dysregulated in ASD children as compared to typically
developing controls.
Ornoy et al. emphasized that an ASD diagnosis is often
an important clinical presentation of some well-known genetic
syndromes in men. They reviewed these syndromes and also
looked at the role of the most important prenatal factors affecting
the fetus throughout pregnancy, which may be associated with
ASD as well as maternal autoimmune diseases, and infections,
which are associated with ASD. Similarly, Nardone and Elliott
reviewed the growing evidence for a complex interaction between
immune system activation in the mother during pregnancy
and epigenetic control in the brain of the fetus that may help
generate an autistic phenotype. They looked at this particularly
because of molecular studies that have highlighted the role
of epigenetics in brain development as a process susceptible
to environmental influences and potentially causative of ASD.
Looking at both the immune state of the mother and the
fetus, Grether et al. found that in both maternal and newborn
there was a significantly lower risk of ASD associated with
higher levels of Toxo IgG. These results support previous
studies indicating that immune factors during early development
may be relevant to the etiology of ASD. Many serological
studies aimed at identifying any abnormalities in the blood
of children with ASD have yielded conflicting results (Kalra
et al., 2015). Nevertheless, various inflammatory cytokines and
immunological markers reflecting immune dysfunction have
been documented in ASD. Preliminary studies even suggest
a correlation between certain antibodies and clinical severity
(Ashwood et al., 2011). In order to counteract the heterogeneity
of ASD, larger studies with broader screening of immune factors
are necessary.
Though there is still much work to do in uncovering
the biological basis for ASD, patterns are beginning
to emerge. The combination of serological data with
genetic data enables researchers to isolate pathways that
demonstrate particular association with ASD. The precise
mechanisms between these networks and the behavioral
symptoms have yet to be fully elucidated. However,
larger studies with more unified diagnostic inclusion
criteria and multidisciplinary testing will hopefully yield
further hints toward identifying the underlying mechanism
of ASD.
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